Meet us at the 2nd annual Spatial Biology for Drug Development Summit. We’re excited to be a Program Partner for the Spatial Biology for Drug Development Summit, returning to Boston for a 2nd year, October 22-24. This year, we’ll dive into the latest in spatial omics...
Events
UPCOMING EVENTS
- Spatial Biology for Immuno-Oncology | January, San Diego, CA (Program Partner)
- American Association for Cancer Research | April, Chicago, IL (Exhibitor)
14th Annual World Clinical Biomarkers and Companion Diagnostics Summit
Meet with us in Boston for World CB & CDx.We’re thrilled to be a Spotlight Partner for the 14th World Clinical Biomarkers and Companion Diagnostics Summit. Join us there to exchange insights with biotech and pharma leaders, researchers, and scientists and to discuss...
Spatial Biology East Coast US 2024
Meet with us at booth #25. As a Gold Sponsor for the third annual Spatial Biology East Coast Congress in Boston, we hope you’ll join our experts and over 350 other industry leaders to discuss the transforming field of spatial biology. Examine how spatial biology can...
2024 Annual Meeting
Meet with us at booth #37085. We help you analyze more data in more depth, so you can produce more effective therapies. Attending the 2024 ASCO® Annual Meeting? Schedule a meeting with our team to discuss our: AI-powered digital pathology solutions Biomarker...
2024 ASGCT Annual Meeting
Are you attending the 2024 ASGCT Annual Meeting? With field-leading keynotes, 200+ scientific sessions, over 7,000 researchers in attendance, and an expanded exhibit hall, the 27th American Society of Gene and Cell Therapy Annual Meeting is the nexus for gene and cell...
AACR Annual Meeting 2024
Meet with us at the AACR Annual Meeting 2024 to learn about our spatial biology solutions. Flagship Biosciences is your source for spatial biology expertise, moving your research forward every step of the way. Our mission is to explore complex biomarkers within the...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Recent Posts
NEWS
Scientist Spotlight: Roger Pearce, MS
Roger Pearce is an Image Analysis Services Manager at Flagship Biosciences. Through expertise in Image Analysis and Digital Pathology, Pearce and his team strive to solve problems for both internal and external clients, pushing their skills and technology to their...
Scientist Spotlight: David Henderson, PhD
Dr. Henderson is Vice President of Computational & Imaging Sciences at Flagship. With a passion for innovative technology and solving problems for clients, Dr. Henderson not only inspires his team but also pushes the boundaries of what’s possible in our industry....
Flagship Biosciences and Offspring Biosciences Partner to Provide Complete Global Assay Development Services from Target Identification to Companion Diagnostics
Unlocking the combined value of Offspring’s innovative pre-clinical solutions with Flagship’s clinical trial data-driven assay solutions. Broomfield, CO, USA and Södertälje, Sweden – January 23, 2024 – Flagship Biosciences, a leader in spatial biology and biomarker...
PUBLICATIONS/POSTERS
Digital and Spatial Characterization of PD-L1 Expression and IVD Performance in the Immune Landscape of Head and Neck Squamous Cell Carcinoma: A Multimodal Approach
Abstract: The anti-PD-L1 antibody (22C3) is used as a companion diagnostic for successful checkpoint inhibitor therapy in head and neck squamous cell carcinoma. The positive predictive value of this assay, however, is less than ideal as a high PD-L1 score does not...
Macrophage Biomarkers CD68 and CD163 Correlate with CRC Patient Survival (Poster No. 2530 at #AACR2022)
Key Takeaways CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1. Lower levels of ‘M1/anti-tumor’ CD68+ or CD68+CD163– cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163+...
Macrophage Biomarkers CD68 and CD163 Correlate with NSCLC Patient Survival (Poster No. 1720 at #AACR2022)
Key Takeaways Image analysis is able to use immune biomarkers to correlate immune cell presence and localization with patient survival in NSCLC. Patient survival correlates with the presence or absence of CD68 and CD163 macrophage markers, but these markers do not...